BeiGene Ltd

Research BeiGene Ltd (ONC) on Bullrun: valuation model: 43.3% overvalued, market cap USD 39.21B, P/E 66.1. Explore financials, valuation history, model signals, and stock context.

Key Metrics

TickerONC
ExchangeNASDAQ
CountrySwitzerland
SectorHealthcare
IndustryBiotechnology
CurrencyUSD
Valuation signal43.3% overvalued
Market capUSD 39.21B
P/E66.1
Financial periodQ2 2026
RevenueUSD 1.71B
Net incomeUSD 237.01M
Free cash flowUSD 414.83M
Gross margin89.8%

Valuation Snapshot

Bullrun's latest valuation model marks BeiGene Ltd as 43.3% overvalued; latest market cap is USD 39.21B; P/E is 66.1.

Peer valuation comparison

Latest P/E is 66.14x versus a Healthcare sector median of 24.46x (170.4% above).

Latest P/E is 66.14x versus a Switzerland median of 20.32x (225.5% above).

Five-year financial history

Year	Revenue	Net income	Free cash flow	Gross margin	Diluted EPS	Cash	Total debt	Equity
FY2025	USD 5.34B	USD 286.93M	USD 941.74M	87.5%	0.19	USD 4.55B	USD 1.02B	USD 4.36B
FY2024	USD 3.81B	-USD 644.79M	-USD 633.29M	84.4%	-0.47	USD 2.63B	USD 1.02B	USD 3.33B
FY2023	USD 2.46B	-USD 881.71M	-USD 1.72B	84.5%	-0.65	USD 3.17B	USD 885.98M	USD 3.54B
FY2022	USD 1.42B	-USD 2.00B	-USD 1.82B	79.8%	-1.49	USD 3.87B	USD 538.12M	USD 4.38B

Valuation history

Year	Snapshot date	Market cap	P/E	Dividend yield	Annual dividend/share
2026	2026-08-25	USD 39.21B	66.1	n/a	n/a
2025	2025-12-31	USD 33.68B	120.6	n/a	n/a
2024	2024-12-31	USD 19.68B	n/a	n/a	n/a
2023	2023-12-29	USD 18.79B	n/a	n/a	n/a
2022	2022-12-30	USD 24.79B	n/a	n/a	n/a
2021	2021-12-31	USD 27.82B	n/a	n/a	n/a

Company Brief

BeGene reported positive Phase 3 results for its product BRUKINSA in frontline mantle cell lymphoma and presented updated data at the European Hematology Association conference, while also seeing revenue grow by 40.2% year-over-year.

The company generated net income with a gross margin of 87.5%, representing an increase from the prior period's 84.4% and reflecting strong profitability alongside significant revenue growth.

Investors will monitor continued performance across its oncology pipeline, including clinical stage products like Sonrotoclax BGB-11417 and other candidates listed in the company profile.

Related stock research

Switzerland stocks Switzerland Healthcare stocks A-Z stock index

Other Healthcare stocks

MOLECULAR PARTNERS SF 1 (6ML) AC Immune SA (ACIU) Addex Therapeutics Ltd (ADXN) Bachem Holding AG (BANB) BB Biotech AG (BBZA) Bioversys AG (BIOV) Basilea Pharmaceutica AG (BSLN) CARDERO RESOURCE (CR5) CRISPR Therapeutics AG (CRSP) Idorsia Ltd (IDIA) MoonLake Immunotherapeutics - Class A (MLTX) Molecular Partners AG (MOLN)

Frequently asked questions

Is BeiGene Ltd overvalued or undervalued?

Bullrun's valuation model currently marks BeiGene Ltd as 43.3% overvalued.

What is BeiGene Ltd's market cap?

BeiGene Ltd's market capitalization is USD 39.21B.

What is BeiGene Ltd's P/E ratio?

BeiGene Ltd's price-to-earnings (P/E) ratio is 66.1.

What does BeiGene Ltd do?

BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally.